Delamanid for the treatment of pulmonary multidrug-resistant tuberculosis

Drugs of Today
R ThakareS Chopra

Abstract

Out of a handful of new drugs currently in clinical trials for the treatment of tuberculosis, delamanid, a nitro-dihydro-imidazole derivative, has successfully emerged. Delamanid is a novel mycolic acid biosynthesis inhibitor that is equally potent against drug-sensitive as well as drug-resistant Mycobacterium tuberculosis. One of the strongest points for delamanid is its inability to be metabolized by cytochrome P450 enzymes, making it a promising candidate to be used in combination therapies for the treatment of tuberculosis and HIV. Additionally, it has successfully completed phase II efficacy trials and has received conditional marketing authorization from the European Medicines Agency.

Citations

Jul 20, 2016·EBioMedicine·María Martínez-HoyosAlfonso Mendoza-Losana
Jun 14, 2017·Antimicrobial Agents and Chemotherapy·Carolina Rodrigues FelixKyle H Rohde
Aug 9, 2017·Expert Opinion on Pharmacotherapy·Malaisamy Muniyandi, Rajeswari Ramachandran
Dec 18, 2020·Frontiers in Cellular and Infection Microbiology·Sapna BajeliAshwani Kumar
Oct 1, 2020·The Cell Surface·Sarah M BattGurdyal S Besra
Dec 21, 2019·Journal of Natural Products·Pavan K BangaloreSrinivas Kantevari

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Related Papers

The New England Journal of Medicine
Maria Tarcela GlerCharles D Wells
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease
A H DiaconP R Donald
Journal of Pharmacology & Pharmacotherapeutics
Alphienes Stanley Xavier, Mageshwaran Lakshmanan
© 2022 Meta ULC. All rights reserved